Undercutting suppression

As the options for combining checkpoint inhibitors with other anticancer agents continue to mount, a new strategy to couple checkpoint blockade with depletion of myeloid-derived suppressor cells (MDSCs) could extend the activity of PD-1 and CTLA4 inhibitors into forms of advanced prostate cancer that until now have remained beyond their reach.

MDSCs are a growing focus in immuno-oncology, where their suppression of T cell activity in the tumor environment provides a target for drug developers looking to unleash the immune system to shrink tumors. ...